Results 181 to 190 of about 25,999 (347)

Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cell–Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19

open access: green, 2022
Caroline Diorio   +25 more
openalex   +2 more sources

Assessing Major Adverse Liver Outcomes With Baclofen Compared to Acamprosate in Compensated Alcohol‐Associated Cirrhosis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
We conducted a nationwide, multicenter cohort study using a target trial emulation framework to compare baclofen and acamprosate in patients with compensated alcohol‐associated cirrhosis. After matching, baclofen initiation was associated with a higher 1‐year risk of major adverse liver outcomes, driven primarily by hepatic encephalopathy, particularly
Yee Hui Yeo   +13 more
wiley   +1 more source

EEG before chimeric antigen receptor T-cell therapy and early after onset of immune effector cell-associated neurotoxicity syndrome

open access: hybrid
Rafael Hernani   +33 more
openalex   +1 more source

Fatal vincristine-induced acute neurotoxicity mimicking Guillain-Barré syndrome

open access: diamond, 2013
Illias Tazi   +3 more
openalex   +1 more source

An Adverse Outcome Pathway for Potential Space Radiation Induced Neurological Diseases [PDF]

open access: yes
Astronauts have begun to spend increasingly longer periods in space, putting themselves in foreign environments in order to explore the unknown. Space radiation is one of the largest health risks faced by astronauts on their missions. The space radiation
Mi, Kaitlyn, Norman, Ryan B.
core   +1 more source

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

open access: yesBritish Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly   +28 more
wiley   +1 more source

Home - About - Disclaimer - Privacy